Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Fabio Stagno Massimo BrecciaMario AnnunziataMalgorzata Monika TrawinskaAlessandra IurloNicola SgherzaCarmen FavaAntonella GozziniLuigiana LucianoIda CarmosinoMassimiliano BonifacioFederica SoràSabrina Leonetti CrescenziMonica CrugnolaGabriele GugliottaSara GalimbertiCristina BucelliGioia ColafigliCostanzo FeoMario TiribelliEndri MauroAntonella Russo RossiAttilio GuariniElisabetta AbruzzeseGianantonio RostiFrancesco Di RaimondoRoberto Latagliata

Published in: Acta oncologica (Stockholm, Sweden) (2021)

These findings, although evaluated in a limited and selected cohort of patients, suggest that DAS might be effective in older patients (aged >75 years) affected by CP-CML with acceptable toxicity.

Keyphrases

chronic myeloid leukemia
clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
oxidative stress
physical activity
randomized controlled trial
patient reported outcomes
disease activity